Compound Radar

Becton, Dickinson and Company (BDX) Stock Analysis

Price $179.10
Market cap $48.78B
Next earnings Nov 5, 2026
Entry status Wait

Last updated Sep 8, 2026

Health Check

Last analyzed Sep 7, 2026

58
58/100 Acceptable
  • Financial Health 40
  • Profitability 60
  • Business Quality 65
  • Balance Sheet 40
  • Cash Flow 80

Why this rating?

Health 58/100 — Acceptable

Strongest Cash Flow 80/100
Softest Balance Sheet 40/100
Wait

Entry timing is weak right now. Quality may be fine; the setup is not.

Company overview

Becton, Dickinson and Company (BDX) is a Medical Instruments & Supplies company in the Healthcare sector. Compound Radar rates Becton, Dickinson and Company 58/100 (Acceptable) due to solid business quality, steady revenue growth, and elevated leverage.

Investment profile

  • Quality Moderate
  • Growth Moderate
  • Balance Sheet Stretched
  • Valuation Attractive

Financial highlights

Valuation

  • P/E 30.99
  • Forward P/E 13.47
  • PEG 1.11
  • EV/Revenue 2.95

Profitability

  • Revenue Growth 5.4%
  • Gross Margin 46.9%
  • Operating Margin 15.7%
  • Net Margin 4.2%
  • ROE 6.6%

Financial strength

  • Cash $709.00M
  • Debt $16.81B
  • Net Cash $-16.10B
  • Free Cash Flow $2.67B
  • Current Ratio 0.87

Similar companies

Peers in Medical Instruments & Supplies, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Medical Instruments & Supplies →

FAQ

How Compound Radar scores and tracks Becton, Dickinson and Company (BDX).

View Methodology & FAQ →